As an independent director of Guizhou Xinbang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), I have strictly complied with the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Securities Law of the People's Republic of China" (hereinafter referred to as the "Securities Law"), the "Code of Corporate Governance for Listed Companies," the "Administrative Measures for Independent Directors of Listed Companies," and other relevant laws, regulations, normative documents, and the "Articles of Association" and "Work System for Independent Directors" of the Company. I have diligently and faithfully performed my duties as an independent director, actively attended relevant meetings, carefully reviewed all proposals submitted to the board of directors, and fully exercised the independent role of an independent director, effectively safeguarding the legitimate rights and interests of the Company and all investors, especially small and medium investors. The following is a report on my performance of independent director duties in 2025:
I. Basic Information
I, Qiu Gang, am a Chinese national, born in 1967, with no permanent overseas residency. I hold a bachelor's degree and a legal professional qualification certificate. I am a member of the 13th CPPCC Guizhou Provincial Committee, an executive member of the 13th Guizhou Provincial Federation of Industry and Commerce, Director of the Legal Committee of the Guizhou Provincial Committee of the China Democratic National Construction Association, a consulting expert on civil and administrative procuratorial matters for the Supreme People's Procuratorate, and an arbitrator of the Guiyang Arbitration Commission. I am currently the Director and Chairman of the Management Committee of Guizhou Zhongchuanglian Law Firm. I have served as an independent director of the Company since July 2021.
I have conducted a self-assessment of my independence during the reporting period and submitted the results to the board of directors. The self-assessment indicates that my position complies with the requirements of the "Administrative Measures for Independent Directors of Listed Companies" and other relevant laws, regulations, normative documents, and the "Articles of Association" and "Work System for Independent Directors" regarding the independence of independent directors, and does not affect my independence.
II. Performance of Duties
(I) Attendance at Board and Shareholder Meetings
In 2025, I actively attended the Company's board and shareholder meetings. I carefully reviewed the proposals at these meetings and exercised my voting rights with prudence, safeguarding the overall interests of the Company and the interests of small and medium investors, thereby fulfilling my duties as an independent director. My meeting attendance is as follows:
| Name | Number of Board Meetings Attended | Number of On-site Board Meetings Attended | Number of Board Meetings Attended via Communication | Number of Board Meetings Attended via Proxy | Number of Board Meetings Missed | Number of Consecutive Board Meetings Missed | Number of Shareholder Meetings Attended |
|---|---|---|---|---|---|---|---|
| Qiu Gang | 4 | 3 | 1 | 0 | 0 | No | 2 |
In 2025, the convening and holding of the Company's board and shareholder meetings complied with the relevant laws, regulations, and normative documents. Major business decisions and other significant matters were processed in accordance with prescribed procedures. I voted in favor of all proposals reviewed by the board of directors at each meeting. I raised no objections to other matters of the Company and did not miss any board meetings.
(II) Participation in Board Special Committee Work
In 2025, as the Chairman of the Ninth Board's Remuneration and Assessment Committee and a member of the Audit Committee, I strictly performed my duties in accordance with relevant regulations and attended all meetings of the special committees to which I was appointed. I carefully reviewed all proposals and expressed my opinions. In 2025, the Company's Ninth Board's Remuneration and Assessment Committee held 1 meeting, and the Ninth Board's Audit Committee held 4 meetings. The work of the special committees is detailed as follows: